BioDlink, a leading global CDMO, proudly congratulates its partner Junshi Biosciences (HKEX-1877; SSE-688180), on receiving Investigational New Drug (IND) approval from the National Medical Products ...

Informed consent is a foundational element of every clinical trial. Yet, the traditional paper-based process has long been ...

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision ...

Clario, a leading provider of digital endpoint data solutions to the clinical trial industry today announced completion of its acquisition of WCG's electronic clinical outcome assessment (eCOA) ...

Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third ...

Symbiosis Completes Successful MHRA Audit of New Sterile Fill/Finish Facility, Expanding Global Manufacturing CapacityStirling, Scotland, 30 April 2025: Symbiosis Pharmaceutical Services (Symbiosis), ...

Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis ...

Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to ...

CEO of the Development Bank of Wales, Giles Thorley, blamed external factors for the performance of the fund that made losses ...

According to the paper published this week, the fund, which was managed by Arix Bioscience plc, paid £7.7m in fees or 15% of ...

Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the ...

A divided board means that the directors will be consumed by the internal dispute and be distracted from managing the ...